Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 571 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Steatosis of Liver Clear all
Not listed Phase 2 Interventional

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

NCT04880187
View directory record Official record
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
AXA1125, Placebo
Drug
Lead sponsor
Axcella Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
57
States / cities
Cullman, Alabama • Tucson, Arizona • Canoga Park, California + 45 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Spironolactone Therapy In Young Women With NASH

NCT03576755
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Phase 2 Interventional

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

NCT06920043
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Phase 2 Interventional

Study of Resmetirom in Children and Adolescents With MASH

NCT07763015
View directory record Official record
Conditions
MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Interventions
Resmetirom
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Multi-Organ Metabolism and Perfusion in NAFLD by Total Body Dynamic PET Scan on EXPLORER

NCT04165343
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH)
Interventions
Positron Emission Tomography (PET) on EXPLORER, Magnetic Resonance Imaging, Echocardiogram and Electrocardiogram, Blood test
Radiation · Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Sep 25, 2026, 9:11 AM EDT
Completed No phase listed Observational

De Novo Lipogenesis in Severity of NAFLD

NCT03683589
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
Interventions
Not listed
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
22 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Weight Loss on Hepatic and Muscle Lipid Content and on Insulin Sensitivity on Obese Adolescents With NAFLD

NCT00585299
View directory record Official record
Conditions
Fatty Liver, Insulin Resistance
Interventions
Low-fat diet, Traditional diet
Other
Lead sponsor
Yale University
Other
Eligibility
10 Years to 21 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic-specific Effects of Fructose on Liver Lipogenesis

NCT03783195
View directory record Official record
Conditions
NAFLD
Interventions
Sugar drink
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional

Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

NCT05292911
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
ALT-801, Placebo
Drug · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
13
States / cities
Montclair, California • Sacramento, California • Miami Lakes, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

NCT07221188
View directory record Official record
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin Alfa, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
57
States / cities
Arcadia, California • Covina, California • Los Angeles, California + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study to Estimate How Common it is to Have Genetic Variants Associated With NAFLD

NCT04494360
View directory record Official record
Conditions
Healthy
Interventions
No intervention
Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
830 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Hollywood, Florida • Lenexa, Kansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional

HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes or Pre-Diabetes

NCT05623189
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
Interventions
HTD1801, Placebo
Drug
Lead sponsor
HighTide Therapeutics (Hong Kong) Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
43
States / cities
Chandler, Arizona • Peoria, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

NCT06419374
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis
Interventions
Pegozafermin, Placebo
Biological · Drug
Lead sponsor
89bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
149
States / cities
Birmingham, Alabama • Homewood, Alabama • Chandler, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 9:11 AM EDT
Active, not recruiting No phase listed Observational

Accurate Point of Care Liver Disease Diagnostics

NCT05986916
View directory record Official record
Conditions
NAFLD, Nonalcoholic Fatty Liver
Interventions
Liverscope® exam, MR exam, FibroScan® exam (optional), Blood draw, Body measurements, Questionnaires
Diagnostic Test · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Not applicable Interventional Results available

Effects of Pitavastatin on Insulin Sensitivity and Liver Fat

NCT02290106
View directory record Official record
Conditions
Obesity, Fatty Liver, Nonalcoholic
Interventions
pitavastatin, PLACEBO
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Sep 25, 2026, 9:11 AM EDT
Terminated Phase 2 Interventional Results available

Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency

NCT02193867
View directory record Official record
Conditions
Lysosomal Acid Lipase Deficiency
Interventions
Sebelipase Alfa
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Up to 8 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 25, 2026, 9:11 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

AGED Diagnostics Liver Disease Assessment

NCT06348563
View directory record Official record
Conditions
NASH With Fibrosis, NAFLD, Healthy
Interventions
AGED Multiple Target Assay in Healthy Controls, AGED Multiple Target Assay in NAFLD Participants, AGED Multiple Target Assay in Fibrosis Participants
Diagnostic Test
Lead sponsor
Active Genomes Expressed Diagnostics, Corp
Industry
Eligibility
18 Years to 65 Years
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 3, 2024 · Synced Sep 25, 2026, 9:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of Leptin Receptors in NASH

NCT00583999
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis, Metabolic Syndrome
Interventions
no interventions, only regular blood-draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1Phase 2 Interventional

Fatty Liver Disease in Obese Children

NCT02117700
View directory record Official record
Conditions
Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
Interventions
N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day, Placebo twice/day
Dietary Supplement · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
7 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 2 Interventional Results available

LIFT Study: A Safety, Tolerability, Efficacy, and Pharmacokinetics Study of TERN-101 in Subjects With Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)

NCT04328077
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
31
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2022 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

NCT03610945
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Fluconazole, Quinidine, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 25, 2026, 9:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers

NCT03213145
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
intraconazole, Rifampin, EDP 305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 25, 2026, 9:11 AM EDT
Recruiting No phase listed Observational

Pathogenesis of Pediatric Nonalcoholic Fatty Liver Disease (NAFLD)

NCT04634643
View directory record Official record
Conditions
NAFLD
Interventions
Usual diet and physical activity
Other
Lead sponsor
Yale University
Other
Eligibility
12 Years to 18 Years
Enrollment
260 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 25, 2026, 9:11 AM EDT